VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2017 | Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?

Paul Cornes, MD, from the University Hospital Bristol NHS Foundation Trust, Bristol, UK, discusses the potential of using an epoetin alfa biosimilar to treat chemotherapy-induced symptomatic anemia. Here, he describes the results supporting or opposing the potential of the biosimilar in treating anemia, obtained from various large clinical studies across the world. Overall, it appears that the majority of researchers “vote strongly in favour of epoetin alfa biosimilars” and if successful, this would greatly benefit patients by allowing more affordable care. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter